燃石医学上涨2.27%，报7.65美元/股，总市值8236.45万美元

Core Insights - The stock price of Burning Stone Medical (BNR) increased by 2.27% on August 18, reaching $7.65 per share, with a total market capitalization of $82.36 million [1] - As of March 31, 2025, the total revenue of Burning Stone Medical was 133 million RMB, reflecting a year-on-year growth of 5.94%, while the net profit attributable to the parent company was -13.5 million RMB, showing a significant year-on-year increase of 88.89% [1] Company Overview - Burning Stone Medical was established in 2014, with a mission to "guard the light of life with science," focusing on providing clinically valuable next-generation sequencing (NGS) for precision oncology [2] - The company's business and research directions primarily cover: 1) tumor patient population testing, holding a leading market share in China; 2) collaborations with global anti-tumor pharmaceutical companies for biomarkers and companion diagnostics; 3) early detection of multiple cancer types [2] - In July 2018, the company received the first certificate for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a milestone in the in vitro diagnostic field [2] - The laboratory located in Guangzhou, China, has passed the technical review by the Guangdong Provincial Clinical Testing Center and obtained quality system certifications from CLIA and CAP; the laboratory in California, USA, has also received CLIA and CAP certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]